HER2+ Breast Cancer Education
The HER2-positive breast cancer landscape has been transformed by antibody-drug conjugates, novel targeted agents, and evolving definitions of HER2 expression. Knowledge Med sessions help community providers navigate treatment selection across lines of therapy through interactive case simulations and real-time clinical decision-making.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing her2-positive breast cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting among multiple HER2-targeted agents and ADCs across lines of therapy
- Understanding HER2-low as a new therapeutic category
- Managing cardiac monitoring and ADC-specific toxicities
- Integrating CNS-active agents for brain metastases
What Sessions Cover
Knowledge Med HER2+ sessions use interactive case simulations to address these topics and more.
- First-line treatment selection in HER2+ metastatic breast cancer
- ADC sequencing: T-DXd, T-DM1, and emerging agents
- HER2-low breast cancer: identifying patients and treatment options
- Managing treatment-related toxicities including ILD and cardiotoxicity
Interactive HER2+ Sessions
Case Simulations
Work through realistic her2-positive breast cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key HER2+ clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Non-Small Cell Lung Cancer
NSCLC — Biomarker-driven first-line therapy selection in advanced NSCLC
Join a HER2+ Session
Third-party, non-promotional her2-positive breast cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session